Mini-HTA for magnetic technology (Magseed) for breast lesions was released in Norway

Norway established in 2013 a framework for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. This framework is called the “New Method.”

In this framework, all innovations should undergo HTA before being funded. If the method concerns only one or two hospitals, the assessment shall be initiated by clinicians and ran at the hospital level. The final report is disseminated via a mini-HTA database. If the method is of national concern, it undergoes Single Technology Appraisal at national level followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum).

Magseed is a magnetic injectable marker that can be implanted by a radiologist during an imaging procedure, such as during ultrasound or X-ray mammographic procedures. The marker can then assist surgeons to find features of interest in soft tissues. In February of 2018, a completed mini-method assessment for the magnetic technology (Magseed) for labeling non-palpable breast lesions was released.

The following conclusions were provided:

• The good level of efficacy was shown by the method in comparison with the gold standard method: use of needle-wire assemblies
• The method was determined as safe
• In addition, the method was positively perceived by the representatives of the Norwegian Breast Cancer Association
• The method should be introduced as part of the clinical routine in the hospital

See the full details in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.